Join Sagimet Biosciences for a virtual event featuring key opinion leader (KOL) Julie Harper, MD, Founding Director and past President of the American Acne and Rosacea Society, who will join company management to discuss the current acne treatment landscape and the unmet need for additional treatment options for moderate to severe acne vulgaris.

Management will discuss the planned Phase 3 clinical trial of denifanstat in moderate to severe acne for the U.S., expected to begin in the second half of 2026. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor with potential as a novel mechanism of action to address moderate to severe acne, a condition that impacts more than 10 million people annually in the U.S.

A live question and answer session will follow the formal presentations.